Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9<i>H</i>-pyrimido[4,5-<i>b</i>]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor
Yujun Zhao(Chinese Academy of Sciences), Shaomeng Wang(University of Michigan–Ann Arbor)
Cited by 42
Related Papers
SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression
|Cancer Research|2014|337
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
|Journal of Medicinal Chemistry|2018|261
A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation
|Nature Communications|2017|93
BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
|PLoS ONE|2014|83
High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction
|Journal of Medicinal Chemistry|2018|62